---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-000938"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:03:57.388285+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences appoints Maria Sainz to Board of Directors and Audit Committee

## Summary
- Maria Sainz elected to Pulse Biosciences Board and Audit Committee effective January 8, 2026.
- Sainz brings over 30 years of healthtech experience; currently CEO of Hyperfine, Inc. (NASDAQ: HYPR).
- Initial stock option grant of 50,000 shares; annual retainer of $55,000 plus $13,000 for Audit Committee.
- Previously CEO of Concentric Medical, Aegea Medical, CardioKinetix; leadership at Guidant and Boston Scientific.
- Serves on boards of Shockwave Medical (SWAV), Spectranetics (SPNC), Avanos (AVNS), Orthofix (OFIX).

## SEC filing metadata
- accession: 0001437749-26-000938
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926000938/0001437749-26-000938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926000938/plse20260106_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-000938
- JSON: https://secwatch.observer/filing/0001437749-26-000938.json
- Plain text: https://secwatch.observer/filing/0001437749-26-000938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.